New combo aims to stop breast cancer return after chemo
NCT ID NCT07400523
First seen Feb 10, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This phase III trial tests whether adding ribociclib to standard hormone therapy (aromatase inhibitor) can prevent breast cancer from coming back in women with hormone receptor-positive, HER2-negative early breast cancer who still have cancer after initial chemotherapy. About 446 women will be randomly assigned to receive either the combination or hormone therapy alone. The main goal is to see if the combination improves survival without cancer recurrence over three years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Guangdong Medical University
RECRUITINGZhanjiang, Guangdong, 524000, China
Contact Phone: •••-•••-••••
-
Shantou Central Hospital
RECRUITINGShantou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ribociclib plus an aromatase inhibitor (letrozole, anastrozole, or exemestane)
What this could lead to
If successful, this combination could reduce the risk of breast cancer returning in patients who still have cancer after initial chemotherapy.
What could go wrong
This is a phase III trial, but results are not yet available. The added drug may cause side effects like low blood cell counts or liver issues, and it may not improve outcomes enough to justify the risks.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.